Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression

Journal of Clinical Psychiatry

Volumn 63, Issue 3, 2002, Pages 232-240

  Miner, Cherri M ^a   Brown, Eileen B ^a   Gonzales, Jill S ^a   Munir, Reema ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COUGHING; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENTERIC COATED TABLET; FEMALE; HAMILTON SCALE; HEADACHE; HEALTH SURVEY; HUMAN; INSOMNIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NERVOUSNESS; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; RELAPSE; RHINITIS; SINUSITIS; TREATMENT OUTCOME; VOMITING; WEIGHT GAIN;

EID: 0036110866     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v63n0310     Document Type: Article

References (22)

1. Long-term treatment of depression
2. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression
3. Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: A meta-analysis
4. The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder
5. Optimal length of continuation therapy in depression: A prospective assessment during long-term fluoxetine treatment
6. Sertraline in the prevention of depression
7. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression
8. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression
9. The prophylactic efficacy of fluoxetine in unipolar depression
10. Citalopram in doses of 20-60 mg is effective in depression relapse prevention: A placebo-controlled 6 month study
11. Patient compliance to a new entericcoated weekly formulation of fluoxetine during continuation treatment of major depressive disorder
12. A rating scale for depression
13. The SF-36 health survey
14. The MOS 36-Item Short-Form Health Survey (SF-36), 1: Conceptual framework and item selection
15. History, description and application of the AMDP system and its derivative systems (AGP, FPDS)
16. Plasma-level response relationships with fluoxetine and zimelidine
17. Conceptualization and rationale for consensus definitions of terms in major depressive disorder
18. Changes in adverse events reported by patients during 6 months of fluoxetine therapy
19. Fluoxetine and norfluoxetine serum concentrations and clinical response in weekly versus daily dosing